Trump's FDA pick helped redraw the vaccine schedule. Now she has to enforce it.

On Aug. 10, 2026, Heidi Overton delivered prepared remarks at the White House criticizing the American Academy of Pediatrics and the CDC over the childhood vaccine schedule. Nine days later, President Trump named her to run the agency that licenses those same vaccines: the FDA.

The nomination lands at a regulatory inflection point. The FDA commissioner seat has been open since Marty Makary departed in May 2026. Overton's nomination was reported by The Guardian. Her confirmation will test how the Senate reads a record that is, in effect, a working draft of how she intends to run the agency.

The clearest evidence of her policy stance is the Aug. 10, 2026 White House event where Overton, introduced as Deputy Assistant to the President for Domestic Policy, delivered prepared remarks criticizing prior guidance from the American Academy of Pediatrics and the CDC on the childhood vaccination schedule. The appearance was a bookend to a Trump executive order on vaccination schedules signed the same day. As FDA commissioner she would inherit the agency that licenses those childhood vaccines and writes the labeling pediatricians and parents rely on.

The MAHA framing matters here. "Make America Healthy Again," the policy banner around HHS Secretary Robert F. Kennedy Jr.'s agenda, has targeted the childhood vaccine schedule and the federal food pyramid. Overton's domestic-policy portfolio included the food-pyramid rewrite. Kennedy endorsed her nomination on Wednesday and described the choice as the toughest of his tenure, citing her judgment, professionalism, and discipline. That endorsement, from a secretary whose agenda Overton has staffed, is the inverse of the independence the FDA is structured to maintain.

Her policy footprint outside the White House includes visible leadership on the administration's food-pyramid rewrite. The food-pyramid rewrite matters because the FDA shares labeling authority with USDA and HHS, and the label rules that flow downstream from that rewrite will land on her desk.

The industry read came quickly. AdvaMed president and CEO Scott Whitaker issued a statement, reported by RAPS, supporting the nomination and pointing to her White House health-policy experience. Device and diagnostics makers tend to favor predictable review timelines over ideology, and Whitaker's response signals that the medtech lobby, at least, does not yet see Overton as a disruption to that predictability.

The Senate's first substantive read will be her public financial disclosure, OGE Form 278e, posted on whitehouse.gov. The PDF is the only public ethics artifact senators and outside groups will have before hearings, and it is where any consulting fees, stock holdings, or outside positions will surface. Senators will want to know whether her outside work or her White House role created obligations the FDA's recusal rules cannot accommodate.

Three early decisions will tell the reader what kind of FDA Overton intends to run. First, whether the Vaccines and Related Biological Products Advisory Committee is reshaped before any schedule votes. Second, the agency's posture on the Risk Evaluation and Mitigation Strategy for mifepristone. Third, what pattern those three choices establish — more than any confirmation hearing statement, they will set the agency's direction for the rest of Trump's term.

Trump's Wednesday Truth Social announcement framed the choice as another loyalist in a health-policy stack the White House has spent eighteen months staffing. The next test is the disclosure form, and what Overton chooses to recuse from once she is confirmed.